Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

被引：0
|
作者：
Wells A. Messersmith
Antonio Jimeno
David Ettinger
Dan Laheru
Julie Brahmer
Dina Lansey
Yasmin Khan
Ross C. Donehower
Yusri Elsayed
Peter Zannikos
Manuel Hidalgo
机构：
[1] University of Colorado Cancer Center,
[2] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[3] Johnson & Johnson Pharmaceutical Research & Development,undefined
[4] L.L.C.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 63卷
关键词：
Dose-finding; Phase I; Gemcitabine; Pharmacokinetics; Trabectedin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：181 / 188
页数：7
相关论文
共 50 条
  • [1] Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
    Messersmith, Wells A.
    Jimeno, Antonio
    Ettinger, David
    Laheru, Dan
    Brahmer, Julie
    Lansey, Dina
    Khan, Yasmin
    Donehower, Ross C.
    Elsayed, Yusri
    Zannikos, Peter
    Hidalgo, Manuel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 181 - 188
  • [2] Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
    Beumer, Jan H.
    Rademaker-Lakhai, Jeany M.
    Rosing, Hilde
    Hillebrand, Michel J. X.
    Bosch, Tessa M.
    Lopez-Lazaro, Luis
    Schellens, Jan H. M.
    Beijnen, Jos H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) : 825 - 837
  • [3] Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
    Jan H. Beumer
    Jeany M. Rademaker-Lakhai
    Hilde Rosing
    Michel J. X. Hillebrand
    Tessa M. Bosch
    Luis Lopez-Lazaro
    Jan H. M. Schellens
    Jos H. Beijnen
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 825 - 837
  • [4] Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
    Forni, Claudia
    Minuzzo, Mario
    Virdis, Emanuela
    Tamborini, Elena
    Simone, Matteo
    Tavecchio, Michele
    Erba, Eugenio
    Grosso, Federica
    Gronchi, Alessandro
    Aman, Pierre
    Casali, Paolo
    D'Incalci, Maurizio
    Pilotti, Silvana
    Mantovani, Roberto
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) : 449 - 457
  • [5] A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours
    Blay, JY
    Le Cesne, A
    Verweij, J
    Scurr, M
    Seynaeve, C
    Bonvalot, S
    Hogendoorn, P
    Jimeno, J
    Evrard, V
    van Glabbeke, M
    Judson, I
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (09) : 1327 - 1331
  • [6] Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors
    William, William N., Jr.
    Lee, Joseph L.
    Shin, Dong M.
    Hong, Waun K.
    Liu, Suyu
    Lee, J. Jack
    Lippman, Scott M.
    Khuri, Fadlo R.
    Kim, Edward S.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (01): : 15 - 19
  • [7] A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors
    Chuk, Meredith K.
    Aikin, Alberta
    Whitcomb, Trish
    Widemann, Brigitte C.
    Zannikos, Peter
    Bayever, Eliel
    Balis, Frank M.
    Fox, Elizabeth
    PEDIATRIC BLOOD & CANCER, 2012, 59 (05) : 865 - 869
  • [8] EFFICACY OF TRABECTEDIN (ET-743) IN PRETREATED PATIENTS WITH ADVANCED/METASTATIC SOFT TISSUE SARCOMA
    Cianci, G.
    De Rosa, P.
    Tonini, G.
    Narducci, F.
    Mentuccia, L.
    Lolli, I
    Ercolino, L.
    Apice, G.
    D'Aprile, M.
    Gamucci, T.
    ANNALS OF ONCOLOGY, 2009, 20
  • [9] Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
    J. H. Beumer
    J. M. Rademaker-Lakhai
    H. Rosing
    L. Lopez-Lazaro
    J. H. Beijnen
    J. H. M. Schellens
    Investigational New Drugs, 2005, 23 : 429 - 436
  • [10] Clinical and pharmacokinetic phase I study of sequential paclitaxel and ET-743 every 2 weeks in patients with advanced solid tumors.
    Chu, QS
    Forouzesh, B
    Schwartz, GH
    Jones, CJ
    Garrison, M
    Goldston, M
    Jimeno, J
    Izquierdo, M
    Flores, L
    Rosing, H
    Tolcher, AW
    Rowinsky, EK
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6080S - 6080S
12345